Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence
- 22 May 2017
- journal article
- review article
- Published by Elsevier BV in Trends in Endocrinology & Metabolism
- Vol. 28 (8), 561-586
- https://doi.org/10.1016/j.tem.2017.04.003
Abstract
No abstract availableKeywords
Funding Information
- US Department of Health and Human Services’ National Institutes of Health (R01 AG025152, R01 DK102694)
This publication has 144 references indexed in Scilit:
- Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagoguesActa Diabetologica, 2012
- Hypoglycemia, Diabetes, and Cardiovascular DiseaseDiabetes Technology & Therapeutics, 2012
- Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the communityReviews in Endocrine and Metabolic Disorders, 2010
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of PioglitazoneCardiovascular Drugs and Therapy, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- The Sulfonylurea Glipizide Does Not Inhibit Ischemic Preconditioning in Anesthetized RabbitsCardiovascular Drugs and Therapy, 2005
- Chlorotoxin does not inhibit volume-regulated, calcium-activated and cyclic AMP-activated chloride channelsBritish Journal of Pharmacology, 2000
- Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heartCardiovascular Research, 1993